Tagging #ENASymp24!

Attending #AACR25? Meet Daniel K. Nomura, Editor-in-Chief of Molecular Cancer Therapeutics, at 9:30 AM CT on Tuesday, April 29 at the AACR Publications Booth 2615. aacrjournals.org/mct Molecular Cancer Therapeutics Dan Nomura

Assistant Editor of Molecular Cancer Therapeutics Danielle Large, PhD will be attending #AACR25! Reach out to her at [email protected] to schedule a meeting to discuss your ongoing research or to learn more about publishing at Molecular Cancer Therapeutics! AACR

Attending the New Drugs on the Horizon session this afternoon at #AACR25? Check out this related article from the April issue, the #FirstDisclosure of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader: doi.org/10.1158/1535-7… #OpenAccess

Cross-journal collection authors Tona Glimer and Michael Kastan at Publications Booth 2615. Don’t miss their featured article: brnw.ch/21wSfUf #AACR25 AACR

Pictured here are corresponding author Hilary A. Kenny, coauthor Tejas Samantaray, and our Assistant Editor Danielle Large, PhD. Congratulations to the authors. UChicago Obstetrics and Gynecology Department

Congratulations to corresponding author Robert Yuan and coauthor Genevive Hernandez, pictured here with Assistant Editor Danielle Large, PhD.

Pictured here are corresponding author Matthew R. Levengood, coauthor Christopher M. Carosino, and our Assistant Editor Danielle Large, PhD. Congratulations to the authors.

Online now! Simultaneous publication with an #AACR25 poster: Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations: doi.org/10.1158/1535-7… AACR

Online now. Simultaneous publication with an #AACR25 poster: 6-((1,4-naphthoquinone-2-yl)methyl)thio-glucose conjugates, a novel targeted approach for advanced #prostatecancer. doi.org/10.1158/1535-7… AACR

Timothy Yap presents his work on the ATR inhibitor elimusertib in tumors with DDR alterations (left), published concurrently with #AACR25, and is pictured with our Assistant Editor Danielle Large, PhD (right).

Online now. Simultaneous publication with an #AACR25 poster: The #FirstDisclosure of HBS-101, a novel inhibitor of midkine, as a therapeutic agent for the treatment of triple negative breast cancer: doi.org/10.1158/1535-7… AACR

Read the editorial from our new Editor-in-Chief Dan Nomura, PhD—A Vision for the Future of Molecular Cancer Therapeutics. doi.org/10.1158/1535-7…

Assistant Editor Danielle Large, PhD, is in Chicago attending the 2025 ASCO Annual Meeting and would love to hear about your research. Connect with her to discuss your work and learn about submitting to the journal. #ASCO25

Associate Editor Danielle Large, PhD is attending #ESMOTATAsia25. Reach out to her at [email protected] to schedule a meeting to discuss your ongoing research or to learn more about publishing at Molecular Cancer Therapeutics.

Molecular Cancer Therapeutics Assistant Editor Danielle Large, PhD, will be at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. If you have a question about the journal or want to discuss your research, contact her at [email protected]. #Targets25

Online now concurrent with a #Targets25 poster, the #FirstDisclosures of G12D-HSP90 dual inhibitors: Dual Inhibitors of #KRASG12D and #HSP90 Are Effective Against KRASG12D Inhibitor Resistance, by Shimamura Lab brnw.ch/21wWSso University of Illinois Cancer Center AACR

Heading to Concurrent Session 3: Protein Degraders at #Targets25? Be sure to check out the new AACR Journals collection—Advances in Targeted Protein Degradation: PROTACs and Molecular Glues brnw.ch/21wWSWp

Curious about opportunities to publish in AACR Journals? Visit AACR booth 101 at #Targets25 on October 24 at 1PM to chat with Molecular Cancer Therapeutics Associate Editor Danielle Large, PhD, about your research.

Attending #Targets25? Read this collection of articles that features recent research and review articles highlighting key advances in PROTAC and molecular glue development. brnw.ch/21wWUMN